NasdaqGS - Nasdaq Real Time Price USD

Vir Biotechnology, Inc. (VIR)

4.6000
+0.0500
+(1.10%)
At close: May 16 at 4:00:00 PM EDT
4.5500
-0.05
(-1.09%)
Pre-Market: 8:00:01 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
14,302
63,712
39,494
1,580,472
1,087,068
Cost of Revenue
786
845
2,765
146,319
65,865
Gross Profit
13,516
62,867
36,729
1,434,153
1,021,203
Operating Expense
625,114
615,037
707,475
601,085
600,452
Operating Income
-611,598
-552,170
-670,746
833,068
420,751
Net Non Operating Interest Income Expense
62,814
71,809
86,990
28,092
439
Other Income Expense
-30,270
-42,744
-44,438
-106,880
128,612
Pretax Income
-579,054
-523,105
-628,194
754,280
549,802
Tax Provision
-1,405
-1,145
-13,077
238,443
21,218
Net Income Common Stockholders
-577,649
-521,960
-615,061
515,837
528,584
Diluted NI Available to Com Stockholders
-577,649
-521,960
-615,061
515,837
528,584
Basic EPS
-4.23
-3.83
-4.59
3.89
4.07
Diluted EPS
-4.23
-3.83
-4.59
3.83
3.96
Basic Average Shares
136,793.9280
136,246.8650
134,130.9240
132,606.7670
129,884.9670
Diluted Average Shares
136,793.9280
136,246.8650
134,130.9240
134,810.9080
133,437.1260
Total Operating Income as Reported
-646,631
-587,165
-684,305
833,068
420,751
Total Expenses
625,900
615,882
710,240
747,404
666,317
Net Income from Continuing & Discontinued Operation
-577,649
-521,960
-615,061
515,837
528,584
Normalized Income
-549,453.5790
-481,518.0460
-580,358.3870
591,856.7600
395,918.9110
Interest Income
62,814
71,809
86,990
28,092
439
Net Interest Income
62,814
71,809
86,990
28,092
439
EBIT
-611,598
-552,170
-670,746
833,068
420,751
EBITDA
-598,689
-537,611
-651,295
839,851
426,562
Reconciled Cost of Revenue
786
845
2,765
146,319
65,865
Reconciled Depreciation
12,909
14,559
19,451
6,783
5,811
Net Income from Continuing Operation Net Minority Interest
-577,649
-521,960
-615,061
515,837
528,584
Total Unusual Items Excluding Goodwill
-28,264
-40,523
-35,447
-111,140
138,049
Total Unusual Items
-28,264
-40,523
-35,447
-111,140
138,049
Normalized EBITDA
-570,425
-497,088
-615,848
950,991
288,513
Tax Rate for Calcs
0
0
0
0.0003
0
Tax Effect of Unusual Items
-68.5790
-81.0460
-744.3870
-35,120.2400
5,383.9110
12/31/2021 - 10/11/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

JANX Janux Therapeutics, Inc.
24.28
+4.34%
 
CYTK Cytokinetics, Incorporated
31.00
+3.89%
 
ITOS iTeos Therapeutics, Inc.
7.81
-2.01%
 
AKRO Akero Therapeutics, Inc.
38.87
-2.73%
 
ALNY Alnylam Pharmaceuticals, Inc.
285.31
+0.67%
 
ARWR Arrowhead Pharmaceuticals, Inc.
15.71
+2.41%
 
RCKT Rocket Pharmaceuticals, Inc.
6.50
-3.35%
 
ALLO Allogene Therapeutics, Inc.
1.1100
+1.83%
 
BBIO BridgeBio Pharma, Inc.
33.84
+0.30%
 
RGNX REGENXBIO Inc.
8.89
+2.89%